Sucraid Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical recognition of csid as a distinct disorder, availability of sacrosidase-based therapies, improved diagnostic testing for digestive enzyme deficiencies, expansion of pediatric gastroenterology care, increased physician awareness of csid.

The growth in the forecast period can be attributed to increasing diagnosis rates of csid, rising focus on personalized nutrition management, expansion of rare disease treatment programs, growing investments in enzyme therapy innovation, improved patient access through specialty pharmacies. Major trends in the forecast period include increasing focus on rare genetic disorder treatments, growing demand for enzyme replacement therapies, expansion of personalized digestive disorder management, rising awareness of csid diagnosis, improved access to prescription enzyme therapies.

The rising incidence of rare genetic disorders is expected to drive the growth of the sucraid market going forward. Rare genetic disorders are conditions that result from mutations or alterations in an individual’s DNA and occur infrequently within the general population. The increasing identification of genetic disorders is attributed to advances in genetic testing that enable earlier and more accurate diagnosis, along with environmental factors and, in certain cases, lifestyle influences that contribute to DNA mutations. Sucraid provides a critical enzyme replacement therapy for patients with congenital sucrase-isomaltase deficiency (CSID), a rare inherited condition, by enabling the digestion of sucrose and maltose that cannot be properly processed due to the absence or deficiency of the sucrase-isomaltase enzyme. For instance, in May 2024, according to the National Health Service, a UK-based government department, approximately 17,000 people in England were living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed each year. Therefore, the increasing incidence of rare genetic disorders is driving the growth of the sucraid market.

Rising healthcare expenditure is expected to support the growth of the sucraid market going forward. Healthcare expenditure represents the total spending on healthcare services and products within a defined period, typically measured annually. The increase in healthcare expenditure is driven by factors such as an aging population, the growing prevalence of chronic diseases, advancements in medical technology, rising pharmaceutical costs, and expanded access to healthcare services. Sucraid, as an effective enzyme replacement therapy for congenital sucrase-isomaltase deficiency (CSID), helps reduce overall healthcare costs by lowering the need for frequent hospitalizations, extensive diagnostic procedures, and long-term complications associated with unmanaged digestive disorders. For instance, in April 2025, according to the Office for National Statistics, a UK-based government agency, provisional estimates indicated that UK healthcare spending reached £317 billion in 2024, reflecting nominal growth of 6.5% and real-term growth of 2.4% compared to 2023. Additionally, total long-term care expenditure increased by 3.1% in real terms in 2023, largely due to higher government spending. Therefore, rising healthcare expenditure is driving growth in the sucraid market.

A key trend in the sucraid market is the pursuit of regulatory approvals for new formulations and manufacturing processes, which improve product availability and patient access. Regulatory approvals involve formal authorization from governmental or regulatory authorities that allows a drug or treatment to be marketed and used by patients. For instance, in September 2023, QOL Medical LLC, a US-based pharmaceutical company, received approval from the US Food and Drug Administration for Sucraid (sacrosidase) in single-use containers intended for patients weighing over 33 pounds (15 kg). This approval helped address prior supply shortages and enhanced patient access by offering a more convenient dosage form with improved stability at room temperature for up to three days. Emphasis on regulatory compliance supports the stabilization of Sucraid’s supply and underscores the role of innovation in improving treatment delivery for rare disease populations.

Major companies operating in the sucraid market are QOL Medical LLC.

North America was the largest region in the sucraid market in 2025. The regions covered in the sucraid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sucraid market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are affecting the sucraid market by increasing costs related to imported pharmaceutical-grade enzymes, formulation excipients, packaging materials, and cold-chain transportation systems. The United States and Europe are most impacted due to dependence on specialized enzyme production and cross-border pharmaceutical supply chains. These tariffs contribute to higher manufacturing and distribution costs, potentially affecting therapy affordability. However, they are also encouraging domestic enzyme production, localized pharmaceutical manufacturing, and greater investment in resilient supply chains for rare disease treatments.

The sucraid market research report is one of a series of new reports that provides sucraid market statistics, including sucraid industry global market size, regional shares, competitors with a sucraid market share, detailed sucraid market segments, market trends and opportunities, and any further data you may need to thrive in the sucraid industry. This sucraid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Sucraid is a prescription medication containing sacrosidase, an enzyme that aids in the digestion of sucrose by breaking it down into glucose and fructose. It is primarily used to manage congenital sucrase-isomaltase deficiency (CSID), a rare inherited disorder in which the body is unable to properly digest sucrose and certain other carbohydrates.

The main clinical indications for Sucraid include congenital sucrase-isomaltase deficiency (CSID), chronic diarrhea associated with CSID, and unexplained gastrointestinal symptoms where CSID is suspected. It is distributed through hospitals and pharmacies and is used by both pediatric and adult patients.

The sucraid market consists of sales of sucraid enzyme supplements, syrups and tablets, and pharmaceuticals for digestive health. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.